Literature DB >> 18832018

Mechanism of action of ZOT-derived peptide AT-1002, a tight junction regulator and absorption enhancer.

Shobha Gopalakrishnan1, Niranjan Pandey, Amir P Tamiz, John Vere, Rosa Carrasco, Robert Somerville, Amit Tripathi, Mark Ginski, Blake M Paterson, Sefik S Alkan.   

Abstract

Tight junctions (TJs) are intercellular structures that control paracellular permeability and epithelial polarity. It is now accepted that TJs are highly dynamic structures that are regulated in response to exogenous and endogenous stimuli. Here, we provide details on the mechanism of action of AT-1002, the active domain of Vibrio cholerae's second toxin, zonula occludens toxin (ZOT). AT-1002, a hexamer peptide, caused the redistribution of ZO-1 away from cell junctions as seen by fluorescence microscopy. AT-1002 also activated src and mitogen activated protein (MAP) kinase pathways, increased ZO-1 tyrosine phosphorylation, and rearrangement of actin filaments. Functionally, AT-1002 caused a reversible reduction in transepithelial electrical resistance (TEER) and an increase in lucifer yellow permeability in Caco-2 cell monolayers. In vivo, co-administration of salmon calcitonin with 1 mg of AT-1002 resulted in a 5.2-fold increase in AUC over the control group. Our findings provide a mechanistic explanation for AT-1002-induced tight junction disassembly, and demonstrate that AT-1002 can be used for delivery of other agents in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18832018     DOI: 10.1016/j.ijpharm.2008.08.047

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  18 in total

1.  Biomaterial-tight junction interaction and potential impacts.

Authors:  Xiangfei Han; Ershuai Zhang; Yuanjie Shi; Boyi Song; Hong Du; Zhiqiang Cao
Journal:  J Mater Chem B       Date:  2019-07-31       Impact factor: 6.331

Review 2.  Pathways and progress in improving drug delivery through the intestinal mucosa and blood-brain barriers.

Authors:  Marlyn Laksitorini; Vivitri D Prasasty; Paul K Kiptoo; Teruna J Siahaan
Journal:  Ther Deliv       Date:  2014-10

Review 3.  Getting Drugs Across Biological Barriers.

Authors:  Rong Yang; Tuo Wei; Hannah Goldberg; Weiping Wang; Kathleen Cullion; Daniel S Kohane
Journal:  Adv Mater       Date:  2017-07-28       Impact factor: 30.849

Review 4.  The role of Haptoglobin and its related protein, Zonulin, in inflammatory bowel disease.

Authors:  Tim Vanuytsel; Séverine Vermeire; Isabelle Cleynen
Journal:  Tissue Barriers       Date:  2013-12-10

5.  Intestinal surfactant permeation enhancers and their interaction with enterocyte cell membranes in a mucosal explant system.

Authors:  E Michael Danielsen; Gert H Hansen
Journal:  Tissue Barriers       Date:  2017-07-03

6.  The active Zot domain (aa 288-293) increases ZO-1 and myosin 1C serine/threonine phosphorylation, alters interaction between ZO-1 and its binding partners, and induces tight junction disassembly through proteinase activated receptor 2 activation.

Authors:  Simeon E Goldblum; Usha Rai; Amit Tripathi; Manjusha Thakar; Luigina De Leo; Nicola Di Toro; Tarcisio Not; Rithwik Ramachandran; Adam C Puche; Morley D Hollenberg; Alessio Fasano
Journal:  FASEB J       Date:  2010-09-17       Impact factor: 5.191

7.  Infectious diarrhea: Cellular and molecular mechanisms.

Authors:  Kim Hodges; Ravinder Gill
Journal:  Gut Microbes       Date:  2010-01

8.  Probing paracellular -versus transcellular tissue barrier permeability using a gut mucosal explant culture system.

Authors:  E Michael Danielsen; Gert H Hansen
Journal:  Tissue Barriers       Date:  2019-04-18

Review 9.  The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate.

Authors:  Shahryar Khaleghi; Josephine M Ju; Abhinav Lamba; Joseph A Murray
Journal:  Therap Adv Gastroenterol       Date:  2016-01       Impact factor: 4.409

Review 10.  Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions?

Authors:  Cezmi A Akdis
Journal:  Nat Rev Immunol       Date:  2021-04-12       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.